The airway stent/lung stent market size was valued at USD 222.98 million in 2025 and estimated to grow from USD 239.52 million in 2026 to reach USD 342.77 million by 2031, at a CAGR of 7.42% during the forecast period (2026-2031). This report is Segmented by Product (Self-Expandable Stents, Balloon- Expandable Stents and More), Material (Metal, Silicone, and More), Type (Tracheobronchial Stents, Laryngeal Stents and More), Indication (Malignant Central Airway Obstruction, Benign Tracheal Stenosis and More), End User (Hospitals, Ambulatory Surgical Centers and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).
Self-expandable devices are reliable in collapse-prone segments, yet physicians increasingly prescribe custom-printed stents for airways distorted by tumors or postsurgical changes. This trend aligns with hospital investment in point-of-care 3D-printing labs that compress turnaround times and lower logistic costs. As these centers mature, non-expandable personalized units will claim a larger slice of the airway stent/lung stent market, even as self-expandable lines remain workhorse solutions for general obstruction.
Metal frameworks remain the default in rapidly progressing tumors due to their high radial strength and radiopaque profiles, which facilitate imaging follow-up. They captured 50.83% of 2025 sales. Yet, biodegradable polymers are the fastest risers, with a 9.07% CAGR through 2031, as clinicians prize temporary support without the burden of removal surgery. Silicone options remain popular in benign diseases because they are less prone to infection and can be easily extracted. Composite designs that combine metal skeletons with polymer linings aim to achieve the best of both worlds, incorporating drug-eluting layers to mitigate granulation.
In adult trials, polydioxanone devices demonstrated 89.7% clinical effectiveness and subsequently resorbed, thereby freeing the airway from foreign material. Iron-scaffold data revealed 95.4% absorption within three years with no loss of mechanical stability. Surface laser texturing promoted endothelial growth while reducing smooth-muscle proliferation by approximately 75%, which can lower the risk of restenosis. As price gaps narrow, polymer adoption will accelerate, shrinking metal’s share of the airway stent/lung stent market.
The Asia-Pacific region is the growth engine, with a 9.2% CAGR projected to 2031. COPD prevalence, 37.8 million cases in India alone, aligns with high urban air-pollution exposure and smoking rates. China’s hospital build-out and a rising middle class are expanding the treated population, despite a 22% decline in medtech investment in 2024 amid tighter capital markets. Japan’s so-called device-lag underscores approval delays, but recent harmonization initiatives aim to shorten the time to market. Together, these dynamics create a sizable addressable base for the airway stent/lung stent market.
Europe offers steady expansion supported by universal healthcare and a strong evidence culture. AnatomikModeling’s collaboration with Toulouse University Hospital showcases the continent’s prowess in custom 3D stents. Multi-center biodegradable trials report 89.7% effectiveness, keeping Europe at the forefront of resorbable research [bmcpulmmed.biomedcentral.com]. The Medical Device Regulation establishes uniform safety benchmarks that facilitate cross-border device adoption, although cost pressures necessitate demonstrable value before large-scale deployment.
Global Airway Stent/Lung Stent Market Trends and Insights
Rising Prevalence of Lung and Chronic Respiratory Disorders
Respiratory Research reported 213.39 million COPD cases in 2024, reflecting better diagnostics and longer survival that in turn keep interventional demand high. Lung-cancer-related airway obstruction frequently requires palliative stents that restore patency and improve breathing comfort. Smoking, which still drives 34.8% of COPD disability-adjusted life-years, and ambient particulate pollution at 22.2% sustain a large patient pipeline. Aging populations amplify case volumes in developed economies, whereas India alone tallied 37.8 million COPD cases, underscoring opportunity in fast-growing Asia-Pacific markets.Growing Preference for Minimally Invasive Procedures
High-frequency jet ventilation using silicone catheters achieved 84% procedural success in 2024 with median operating times of 35 minutes and no postoperative complications, strengthening the clinical case for bronchoscopic stenting over open surgery.Hospitals embrace outpatient protocols to contain costs and accelerate recovery, while cone-beam CT and digital tomosynthesis sharpen placement accuracy. Robotic bronchoscopy systems deliver diagnostic yields of 88-94% for peripheral lesions, further easing physician adoption.Availability of Alternative Interventions
Balloon dilation solves many benign strictures with 88.9% efficacy and leaves no implant behind, while surgical reconstruction offers definitive cures for localized stenosis in fit patients. Techniques such as laser, cryotherapy, and argon plasma coagulation recanalize blocked airways quickly, and Montgomery T-tubes provide another removable option in post-tracheotomy stenosis.Other drivers and restraints analyzed in the detailed report include:
- Rapid Material Innovation in 3D-Printed and Drug-Eluting Bioresorbable Stents
- Benefits Linked to Pulmonary Stent Usage
- Device-Related Complications
Segment Analysis
Self-expandable devices accounted for 58.96% of 2025 revenue, confirming their versatility in treating both benign and malignant obstructions. These stents expand gently after deployment and maintain steady radial force, helping physicians manage variable airway diameters. Balloon-expandable units are designed for scenarios that require precise sizing, such as pediatric tracheal narrowing. Non-expandable and 3D-printed custom designs are projected to achieve an 8.78% CAGR through 2031. The shift toward personalized implants reflects a growing awareness that geometric differences necessitate tailored solutions. AnatomikModeling and Toulouse University Hospital executed one of the earliest custom placements in 2016 and have since demonstrated improved migration profiles in validation studies. Michigan Medicine’s 2025 infant trial marks a new frontier in resorbable, bespoke devices.Self-expandable devices are reliable in collapse-prone segments, yet physicians increasingly prescribe custom-printed stents for airways distorted by tumors or postsurgical changes. This trend aligns with hospital investment in point-of-care 3D-printing labs that compress turnaround times and lower logistic costs. As these centers mature, non-expandable personalized units will claim a larger slice of the airway stent/lung stent market, even as self-expandable lines remain workhorse solutions for general obstruction.
Metal frameworks remain the default in rapidly progressing tumors due to their high radial strength and radiopaque profiles, which facilitate imaging follow-up. They captured 50.83% of 2025 sales. Yet, biodegradable polymers are the fastest risers, with a 9.07% CAGR through 2031, as clinicians prize temporary support without the burden of removal surgery. Silicone options remain popular in benign diseases because they are less prone to infection and can be easily extracted. Composite designs that combine metal skeletons with polymer linings aim to achieve the best of both worlds, incorporating drug-eluting layers to mitigate granulation.
In adult trials, polydioxanone devices demonstrated 89.7% clinical effectiveness and subsequently resorbed, thereby freeing the airway from foreign material. Iron-scaffold data revealed 95.4% absorption within three years with no loss of mechanical stability. Surface laser texturing promoted endothelial growth while reducing smooth-muscle proliferation by approximately 75%, which can lower the risk of restenosis. As price gaps narrow, polymer adoption will accelerate, shrinking metal’s share of the airway stent/lung stent market.
Complete Report Scope:
- By Product
- Self-Expandable Stents
- Balloon-Expandable Stents
- Non-Expandable / Customized 3D-Printed Stents
- By Material
- Metal
- Silicone
- Hybrid (Covered / Composite)
- Bioresorbable Polymers
- By Type
- Tracheobronchial Stents
- Laryngeal Stents
- Y-Shaped Carinal Stents
- By Indication
- Malignant Central Airway Obstruction
- Benign Tracheal Stenosis
- Post-Lung-Transplant Airway Complications
- Tracheoesophageal Fistula
- By End User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Pulmonology Clinics
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America generated 38.45% of revenue in 2025, underpinned by advanced reimbursement policies and rapid adoption of precision placement technologies. The FDA’s 2024 De Novo clearance for Peytant’s stent system demonstrates a supportive regulatory climate. The forthcoming Quality System Regulation alignment with ISO standards by 2026 will streamline manufacturing compliance and help innovative devices reach hospitals more quickly. Robotic bronchoscopy diagnostic yields of up to 94% solidify the region’s leadership in technology-driven care. While Medicare covers core interventional pulmonology codes, payment gaps persist for customized implants, tempering near-term adoption of 3D-printed solutions.The Asia-Pacific region is the growth engine, with a 9.2% CAGR projected to 2031. COPD prevalence, 37.8 million cases in India alone, aligns with high urban air-pollution exposure and smoking rates. China’s hospital build-out and a rising middle class are expanding the treated population, despite a 22% decline in medtech investment in 2024 amid tighter capital markets. Japan’s so-called device-lag underscores approval delays, but recent harmonization initiatives aim to shorten the time to market. Together, these dynamics create a sizable addressable base for the airway stent/lung stent market.
Europe offers steady expansion supported by universal healthcare and a strong evidence culture. AnatomikModeling’s collaboration with Toulouse University Hospital showcases the continent’s prowess in custom 3D stents. Multi-center biodegradable trials report 89.7% effectiveness, keeping Europe at the forefront of resorbable research [bmcpulmmed.biomedcentral.com]. The Medical Device Regulation establishes uniform safety benchmarks that facilitate cross-border device adoption, although cost pressures necessitate demonstrable value before large-scale deployment.
List of Companies Covered in this Report:
- Boston Scientific
- Taewoong Medical Co. Ltd.
- Micro-Tech (Nanjing) Co. Ltd.
- Merit Medical Systems
- Cook Group
- Endo-Flex
- Efer Endoscopy
- Bess Medizintechnik
- Standard Sci Tech
- E. Benson Hood Laboratories
- Novatech
- M.I. Tech Co. Ltd.
- A.B. Polyp Co. Ltd.
- Stening SRL
- Hyundai Medical Co. Ltd.
- Bentley Innomed GmbH
- Olympus
- Medtronic
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size and Growth Forecasts (Value-USD)
6 Competitive Landscape
7 Market Opportunities and Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Boston Scientific Corporation
- Taewoong Medical Co. Ltd.
- Micro-Tech (Nanjing) Co. Ltd.
- Merit Medical Systems Inc.
- Cook Group Incorporated
- Endo-Flex GmbH
- Efer Endoscopy
- Bess Medizintechnik GmbH
- Standard Sci Tech Inc.
- E. Benson Hood Laboratories Inc.
- Novatech SA
- M.I. Tech Co. Ltd.
- A.B. Polyp Co. Ltd.
- Stening SRL
- Hyundai Medical Co. Ltd.
- Bentley Innomed GmbH
- Olympus Corporation
- Medtronic plc
